An investigation for investors in MediciNova, Inc. (NASDAQ: MNOV) shares over potential securities laws violations by MediciNova, Inc. (NASDAQ: MNOV) was announced and NASDAQ: MNOV stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 05/21/2019 -- An investigation was announced on behalf of investors of MediciNova, Inc. (NASDAQ: MNOV) shares over potential securities laws violations by MediciNova, Inc.
Investors who purchased shares of MediciNova, Inc. (NASDAQ: MNOV), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by MediciNova, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
La Jolla, CA based MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. Shares of MediciNova, Inc. (NASDAQ: MNOV) declined from as high as $13.00 per share on May 16, 2019 to as low as $10.29 per share on May 20, 2019.
Those who purchased shares of MediciNova, Inc. (NASDAQ: MNOV) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels